A First-in-Human Study of KK2223 in Participants with T-cell Non-Hodgkin Lymphoma

2025-522523-96-00 Protocol 2223-001 Human pharmacology (Phase I) - First administration to humans Authorised, recruitment pending

Status Authorised, recruitment pending · 2 EU/EEA countries · 8 sites · Protocol 2223-001

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - First administration to humans
Status Authorised, recruitment pending
Participants planned 72
Countries 2
Sites 8

T-cell Non-Hodgkin Lymphoma

Key facts

Sponsor
Kyowa Kirin Inc.
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Neoplasms [C04]
Decision date (initial)
2026-04-01
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

External identifiers

EU CT number
2025-522523-96-00
ClinicalTrials.gov
NCT07192471

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

T-cell Non-Hodgkin Lymphoma

VersionLevelCodeTermSystem organ class
28.0 PT 10011677 Cutaneous T-cell lymphoma 100000004864
28.0 HLGT 10025321 Lymphomas non-Hodgkin´s T-cell 10029104
28.0 PT 10034623 Peripheral T-cell lymphoma unspecified 100000004864

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Kyowa Kirin Inc.

Sponsor organisation
Kyowa Kirin Inc.
Address
510 Carnegie Center Suite 600
City
Princeton
Postcode
08540-6241
Country
United States

Scientific contact point

Organisation
Kyowa Kirin Inc.
Contact name
Corporate Communications

Public contact point

Organisation
Kyowa Kirin Inc.
Contact name
Corporate Communications

Locations

2 EU/EEA countries · 8 investigational sites

By country

CountryMS statusPlanned subjectsSites
Italy Authorised, recruitment pending 17 4
Spain Authorised, recruitment pending 17 4
Rest of world
United States
38

Investigational sites

Italy

4 sites · Authorised, recruitment pending
Azienda Ospedaliero-Universitaria Di Bologna IRCCS Istituto Di Ricerca E Di Cura A Carattere Scientifico
ITL004: UOC Ematologia, Via Pietro Albertoni 15, 40138, Bologna
Istituto Di Candiolo Fondazione Del Piemonte Per L'Oncologia IRCCS
ITL003: Oncologia Medica ed Ematologia, Strada Provinciale 142 Orba Km 3,95, 10060, Candiolo
Azienda Ospedaliera Universitaria Citta Della Salute E Della Scienza Di Torino
ITL002: Ematologia Universitaria, Corso Bramante 88, 10126, Turin
Azienda Socio Sanitaria Territoriale Papa Giovanni Xxiii
ITL001: Ematologia, Piazza Oms 1, 24127, Bergamo

Spain

4 sites · Authorised, recruitment pending
Clinica Universidad De Navarra
ESP001: Hematology and Hemotherapy, Pio XII Etorbidea 36, 31008, Pamplona
Hospital Clinic De Barcelona
ESP002: Hematología, Calle Villarroel 170, 08036, Barcelona
Institut Catala D'oncologia
ESP003: Hematologia, Avinguda De La Gran Via De L'hospitalet 199-203, 08908, L'hospitalet De Llobregat
Clinica Universidad De Navarra
ESP004: Hematología, Calle Marquesado De Santa Marta 1, 28027, Madrid

Application history

1 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2025-12-08 Spain Acceptable with conditions
2026-03-30
2026-04-01